For allergies, using variable domain of heavy chain of heavy-chain antibody (VHH) as a replacement for traditional scFv can achieve specific recognition of CD19 without causing allergic reactions and can to some extent address the issue of short-term relapse after treatment with mouse-derived CAR-T cells (57, 58). The gene discussed is CD19; the disease is allergic disease.